Trade Seres Therapeutics Inc - MCRB CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026346% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004124% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Seres Therapeutics Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 1.1 |
Open* | 1.06 |
1-Year Change* | -85.07% |
Day's Range* | 1.05 - 1.08 |
52 wk Range | 0.91-7.30 |
Average Volume (10 days) | 3.96M |
Average Volume (3 months) | 73.54M |
Market Cap | 135.07M |
P/E Ratio | -100.00K |
Shares Outstanding | 129.26M |
Revenue | 127.24M |
EPS | -1.13 |
Dividend (Yield %) | N/A |
Beta | 2.52 |
Next Earnings Date | Mar 5, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 4, 2023 | 1.10 | 0.05 | 4.76% | 1.05 | 1.12 | 1.02 |
Dec 1, 2023 | 1.04 | 0.05 | 5.05% | 0.99 | 1.06 | 0.96 |
Nov 30, 2023 | 1.03 | -0.08 | -7.21% | 1.11 | 1.13 | 0.99 |
Nov 29, 2023 | 1.09 | -0.02 | -1.80% | 1.11 | 1.18 | 1.09 |
Nov 28, 2023 | 1.10 | -0.02 | -1.79% | 1.12 | 1.13 | 1.08 |
Nov 27, 2023 | 1.13 | 0.05 | 4.63% | 1.08 | 1.14 | 1.04 |
Nov 24, 2023 | 1.12 | 0.05 | 4.67% | 1.07 | 1.17 | 1.07 |
Nov 22, 2023 | 1.08 | 0.03 | 2.86% | 1.05 | 1.10 | 0.98 |
Nov 21, 2023 | 1.02 | -0.04 | -3.77% | 1.06 | 1.15 | 1.01 |
Nov 20, 2023 | 0.95 | -0.43 | -31.16% | 1.38 | 1.38 | 0.94 |
Nov 17, 2023 | 1.39 | 0.23 | 19.83% | 1.16 | 1.41 | 1.14 |
Nov 16, 2023 | 1.14 | -0.05 | -4.20% | 1.19 | 1.20 | 1.09 |
Nov 15, 2023 | 1.18 | -0.01 | -0.84% | 1.19 | 1.33 | 1.18 |
Nov 14, 2023 | 1.21 | 0.16 | 15.24% | 1.05 | 1.21 | 1.05 |
Nov 13, 2023 | 1.04 | 0.04 | 4.00% | 1.00 | 1.05 | 0.96 |
Nov 10, 2023 | 0.99 | 0.02 | 2.06% | 0.97 | 0.99 | 0.94 |
Nov 9, 2023 | 0.98 | -0.05 | -4.85% | 1.03 | 1.03 | 0.90 |
Nov 8, 2023 | 1.01 | -0.18 | -15.13% | 1.19 | 1.19 | 1.00 |
Nov 7, 2023 | 1.19 | 0.06 | 5.31% | 1.13 | 1.20 | 1.05 |
Nov 6, 2023 | 1.11 | -0.17 | -13.28% | 1.28 | 1.30 | 1.11 |
Seres Therapeutics Inc Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, March 5, 2024 | ||
Time (UTC) 13:30 | Country US
| Event Q4 2023 Seres Therapeutics Inc Earnings Release Q4 2023 Seres Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 7.128 | 144.927 | 33.215 | 34.505 | 28.267 |
Revenue | 7.128 | 144.927 | 33.215 | 34.505 | 28.267 |
Total Operating Expense | 253.618 | 209.42 | 121.345 | 106.381 | 128.551 |
Selling/General/Admin. Expenses, Total | 85.796 | 69.261 | 30.775 | 24.748 | 32.596 |
Research & Development | 166.818 | 141.891 | 90.57 | 80.141 | 95.955 |
Operating Income | -246.49 | -64.493 | -88.13 | -71.876 | -100.284 |
Interest Income (Expense), Net Non-Operating | -2.962 | -0.04 | -1.978 | 0.531 | 1.172 |
Net Income Before Taxes | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Net Income After Taxes | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Net Income Before Extra. Items | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Net Income | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Total Adjustments to Net Income | |||||
Income Available to Common Excl. Extra. Items | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Income Available to Common Incl. Extra. Items | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Diluted Net Income | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Diluted Weighted Average Shares | 108.077 | 91.7029 | 79.7892 | 56.6492 | 40.7435 |
Diluted EPS Excluding Extraordinary Items | -2.31462 | -0.71511 | -1.11703 | -1.2406 | -2.42841 |
Diluted Normalized EPS | -2.31462 | -0.71511 | -1.11703 | -1.21426 | -2.42841 |
Other, Net | -0.705 | -1.045 | 0.981 | 1.066 | 0.17 |
Total Extraordinary Items | 0 | ||||
Dividends per Share - Common Stock Primary Issue | |||||
Unusual Expense (Income) | 0 | 0 | 1.492 | ||
Other Operating Expenses, Total | 1.004 | -1.732 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 126.473 | -0.522 | 0.975 | 3.444 | 1.216 |
Revenue | 126.473 | -0.522 | 0.975 | 3.444 | 1.216 |
Total Operating Expense | 76.949 | 70.046 | 69.282 | 62.551 | 64.541 |
Selling/General/Admin. Expenses, Total | 28.051 | 22.47 | 22.404 | 18.384 | 20.335 |
Research & Development | 46.792 | 43.969 | 46.22 | 43.116 | 43.935 |
Operating Income | 49.524 | -70.568 | -68.307 | -59.107 | -63.325 |
Interest Income (Expense), Net Non-Operating | -1.461 | -0.916 | -0.466 | -0.862 | -1.106 |
Other, Net | -1.511 | 0.31 | -0.023 | -0.033 | -0.304 |
Net Income Before Taxes | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Net Income After Taxes | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Net Income Before Extra. Items | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Net Income | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Income Available to Common Excl. Extra. Items | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Income Available to Common Incl. Extra. Items | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Diluted Net Income | 46.552 | -71.174 | -68.796 | -60.002 | -64.735 |
Diluted Weighted Average Shares | 129.845 | 125.863 | 125.166 | 122.527 | 92.2554 |
Diluted EPS Excluding Extraordinary Items | 0.35852 | -0.56549 | -0.54964 | -0.4897 | -0.70169 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | 0.35852 | -0.56549 | -0.54964 | -0.4897 | -0.70169 |
Other Operating Expenses, Total | 2.106 | 3.607 | 0.658 | 1.051 | 0.271 |
Unusual Expense (Income) |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 194.764 | 303.628 | 268.777 | 100.189 | 92.665 |
Cash and Short Term Investments | 181.341 | 290.706 | 253.616 | 94.816 | 85.82 |
Cash & Equivalents | 163.03 | 180.002 | 116.049 | 65.126 | 85.82 |
Short Term Investments | 18.311 | 110.704 | 137.567 | 29.69 | 0 |
Prepaid Expenses | 13.423 | 12.922 | 5.774 | 3.588 | 6.845 |
Total Assets | 348.784 | 354.859 | 342.94 | 132.44 | 120.472 |
Property/Plant/Equipment, Total - Net | 133.969 | 36.146 | 22.938 | 30.851 | 26.294 |
Property/Plant/Equipment, Total - Gross | 179.009 | 76.414 | 57.258 | 58.593 | 46.595 |
Accumulated Depreciation, Total | -45.04 | -40.268 | -34.32 | -27.742 | -20.301 |
Long Term Investments | 0 | 0.495 | 49.825 | ||
Other Long Term Assets, Total | 20.051 | 14.59 | 1.4 | 1.4 | 1.513 |
Total Current Liabilities | 85.596 | 82.258 | 46.415 | 45.993 | 42.041 |
Accounts Payable | 17.44 | 13.735 | 4.018 | 4.859 | 6.415 |
Accrued Expenses | 18.31 | 15.826 | 11.849 | 9.065 | 5.02 |
Notes Payable/Short Term Debt | 0.456 | 0 | 0.454 | 0 | 0 |
Other Current Liabilities, Total | 49.39 | 52.697 | 30.094 | 32.069 | 30.606 |
Total Liabilities | 338.001 | 223.352 | 168.19 | 180.764 | 168.517 |
Total Long Term Debt | 50.591 | 24.643 | 24.639 | 24.648 | 0 |
Other Liabilities, Total | 201.814 | 116.451 | 97.136 | 110.123 | 126.476 |
Total Equity | 10.783 | 131.507 | 174.75 | -48.324 | -48.045 |
Common Stock | 0.125 | 0.092 | 0.091 | 0.07 | 0.041 |
Additional Paid-In Capital | 875.181 | 745.829 | 723.482 | 411.255 | 341.284 |
Retained Earnings (Accumulated Deficit) | -864.511 | -614.354 | -548.776 | -459.649 | -389.37 |
Other Equity, Total | -0.012 | -0.06 | -0.047 | 0 | |
Total Liabilities & Shareholders’ Equity | 348.784 | 354.859 | 342.94 | 132.44 | 120.472 |
Total Common Shares Outstanding | 125.222 | 91.8894 | 91.4592 | 70.1432 | 40.9367 |
Redeemable Preferred Stock | |||||
Total Receivables, Net | 0 | 9.387 | 1.785 | ||
Accounts Receivable - Trade, Net | 0 | 9.387 | 1.785 | ||
Long Term Debt | 50.591 | 24.643 | 24.639 | 24.648 | |
Current Port. of LT Debt/Capital Leases | 0 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 214.394 | 251.238 | 116.081 | 194.764 | 247.513 |
Cash and Short Term Investments | 169.912 | 229.52 | 106.544 | 181.341 | 233.003 |
Cash & Equivalents | 169.912 | 229.52 | 94.841 | 163.03 | 205.398 |
Short Term Investments | 0 | 0 | 11.703 | 18.311 | 27.605 |
Total Receivables, Net | 16.857 | 7.559 | |||
Accounts Receivable - Trade, Net | |||||
Prepaid Expenses | 9.1 | 8.819 | 9.537 | 13.423 | 14.51 |
Total Assets | 367.699 | 406.387 | 270.194 | 348.784 | 311.868 |
Property/Plant/Equipment, Total - Net | 131.671 | 134.309 | 133.22 | 133.969 | 43.231 |
Property/Plant/Equipment, Total - Gross | 181.322 | 182.276 | 179.66 | 179.009 | 88.501 |
Accumulated Depreciation, Total | -49.651 | -47.967 | -46.44 | -45.04 | -45.27 |
Long Term Investments | 0 | 0 | |||
Other Long Term Assets, Total | 21.634 | 20.84 | 20.893 | 20.051 | 21.124 |
Total Current Liabilities | 79.225 | 77.898 | 63.818 | 85.596 | 81.819 |
Accounts Payable | 8.958 | 12.922 | 12.297 | 17.44 | 10.449 |
Accrued Expenses | 19.759 | 17.158 | 11.661 | 18.31 | 18.114 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0.456 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 50.508 | 47.818 | 39.86 | 49.39 | 53.256 |
Total Liabilities | 382.822 | 383.773 | 318.065 | 338.001 | 244.283 |
Total Long Term Debt | 101.135 | 100.742 | 51.234 | 50.591 | 50.857 |
Long Term Debt | 101.135 | 100.742 | 51.234 | 50.591 | 50.857 |
Other Liabilities, Total | 202.462 | 205.133 | 203.013 | 201.814 | 111.607 |
Total Equity | -15.123 | 22.614 | -47.871 | 10.783 | 67.585 |
Common Stock | 0.129 | 0.128 | 0.127 | 0.125 | 0.124 |
Additional Paid-In Capital | 921.735 | 911.62 | 887.685 | 875.181 | 863.294 |
Retained Earnings (Accumulated Deficit) | -936.987 | -889.133 | -935.685 | -864.511 | -795.715 |
Other Equity, Total | 0 | -0.001 | 0.002 | -0.012 | -0.118 |
Total Liabilities & Shareholders’ Equity | 367.699 | 406.387 | 270.194 | 348.784 | 311.868 |
Total Common Shares Outstanding | 128.631 | 128.038 | 126.593 | 125.222 | 124.411 |
Total Inventory | 18.525 | 5.34 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -250.157 | -65.578 | -89.127 | -70.279 | -98.942 |
Cash From Operating Activities | -228.815 | 6.688 | -93.61 | -76.52 | -62.854 |
Cash From Operating Activities | 6.629 | 5.947 | 6.578 | 7.603 | 7.862 |
Non-Cash Items | 33.103 | 24.789 | 12.136 | 10.783 | 16.427 |
Cash Interest Paid | 4.926 | 2.446 | 2.453 | 0.221 | 0 |
Changes in Working Capital | -18.39 | 41.53 | -23.197 | -24.627 | 11.799 |
Cash From Investing Activities | 82.428 | 64.088 | -158.891 | -30.518 | 112.318 |
Capital Expenditures | -9.821 | -9.566 | -0.591 | -1.002 | -1.937 |
Other Investing Cash Flow Items, Total | 92.249 | 73.654 | -158.3 | -29.516 | 114.255 |
Cash From Financing Activities | 129.602 | 1.178 | 303.424 | 86.231 | 0.268 |
Issuance (Retirement) of Stock, Net | 103.903 | 2.126 | 283.524 | 61.656 | 0.268 |
Net Change in Cash | -16.786 | 71.953 | 50.923 | -20.807 | 49.732 |
Financing Cash Flow Items | 0 | 19.9 | -0.425 | ||
Issuance (Retirement) of Debt, Net | 25.699 | -0.948 | 25 | ||
Foreign Exchange Effects | -0.001 | -0.001 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -71.174 | -250.157 | -181.361 | -121.359 | -56.624 |
Cash From Operating Activities | -76.584 | -228.815 | -175.922 | -116.342 | -66.445 |
Cash From Operating Activities | 1.4 | 6.629 | 5.002 | 3.255 | 1.57 |
Non-Cash Items | 12.527 | 33.103 | 23.324 | 14.302 | 5.607 |
Cash Interest Paid | 1.737 | 4.926 | 3.282 | 1.836 | 0.558 |
Changes in Working Capital | -19.337 | -18.39 | -22.887 | -12.54 | -16.998 |
Cash From Investing Activities | 2.739 | 82.428 | 76.502 | 36.371 | 12.972 |
Capital Expenditures | -4.068 | -9.821 | -6.36 | -5.113 | -2.95 |
Other Investing Cash Flow Items, Total | 6.807 | 92.249 | 82.862 | 41.484 | 15.922 |
Cash From Financing Activities | 5.656 | 129.602 | 125.005 | 26.978 | 26.848 |
Issuance (Retirement) of Stock, Net | 5.656 | 103.903 | 102.585 | 1.279 | 1.149 |
Net Change in Cash | -68.189 | -16.786 | 25.583 | -52.993 | -26.625 |
Financing Cash Flow Items | -3.279 | ||||
Issuance (Retirement) of Debt, Net | 0 | 25.699 | 25.699 | 25.699 | 25.699 |
Foreign Exchange Effects | -0.001 | -0.002 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Flagship Ventures | Venture Capital | 18.0314 | 23117045 | 0 | 2023-06-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 14.9645 | 19185208 | 273750 | 2023-06-30 | LOW |
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 8.888 | 11394801 | -105719 | 2023-06-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 6.6807 | 8564935 | 4796626 | 2023-06-30 | LOW |
Nestle SA | Corporation | 5.9234 | 7594038 | -298852 | 2022-07-18 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.2306 | 6705853 | 1327621 | 2023-06-30 | LOW |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 4.7369 | 6072942 | -5227873 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1596 | 5332847 | -505131 | 2023-06-30 | LOW |
Eversept Partners, LP | Hedge Fund | 2.3999 | 3076756 | 540091 | 2023-06-30 | HIGH |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 1.95 | 2500000 | 1205000 | 2023-06-30 | LOW |
Soleus Capital Management, L.P. | Hedge Fund | 1.5959 | 2045983 | 2045983 | 2023-06-30 | HIGH |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.5299 | 1961358 | 325849 | 2023-06-30 | LOW |
Millennium Management LLC | Hedge Fund | 1.3727 | 1759914 | 1351434 | 2023-06-30 | HIGH |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.086 | 1392356 | 727622 | 2023-06-30 | LOW |
BofA Global Research (US) | Research Firm | 0.9312 | 1193896 | 810048 | 2023-06-30 | LOW |
Point72 Asset Management, L.P. | Hedge Fund | 0.7959 | 1020400 | 727600 | 2023-06-30 | HIGH |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.78 | 1000000 | 0 | 2023-09-30 | LOW |
Great Point Partners, LLC | Hedge Fund | 0.7317 | 938067 | 938067 | 2023-06-30 | HIGH |
Hudson Bay Capital Management LP | Hedge Fund | 0.6864 | 880000 | 355000 | 2023-06-30 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.6183 | 792699 | 160286 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Seres Therapeutics Inc Company profile
About Seres Therapeutics Inc
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis and SER-155 to treat enteric bacterial pathogens.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Seres Therapeutics Inc revenues increased from $33.2M to $144.9M. Net loss decreased 26% to $65.6M. Revenues reflect Collaboration revenue - related party increase from $11.9M to $143.9M. Lower net loss reflects Interest income increase from $946K to $2.9M (income), Interest expense remaining flat at $2.9M (expense).
Industry: | Bio Therapeutic Drugs |
200 Sidney St
CAMBRIDGE
MASSACHUSETTS 02139-4218
US
Income Statement
- Annual
- Quarterly
News

December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com